Ballicules.com

Dexamethasone

DECADRON

What it isLong-acting glucocorticoid with negligible mineralocorticoid effect; cerebral edema, croup, antiemesis and COVID-19.

Why this oneIts potency and long half-life allow single or once-daily dosing, and the lack of sodium retention suits raised intracranial pressure.

What limits itProfound axis suppression from the long duration. Hyperglycemia is prominent; CYP3A4 substrate and inducer.

FDA-approved for

Off-label

FDA label

FDA dosingPopulationStartTargetMax
Corticosteroid-responsive disordersAdults0.75–9 mg/daylowest effective maintenance dosevaries by disease
Corticosteroid-responsive disordersPediatric0.02–0.3 mg/kg/day divided TID–QIDindividualized
Acute exacerbation of multiple sclerosisAdults30 mg/day x 1 weekthen 4–12 mg every other day x 1 month

Renal Undefined

Hepatic Undefined

Instructions

Contraindications

Cautions

Adverse reactions

Pregnancy Undefined

Lactation Undefined

NO BOXED WARNINGS

Principal riskAdrenal suppression; the longest-acting corticosteroid

Cost, est. cash$4–$300/month

Generic entry1982

Classes and tags

Clinical profile

Therapeutic safety burden3 / 4
Overdose danger2 / 4
Weight-gain liability3 / 4
Sedation liability0 / 4
QT / Torsades0 / 4
Direct muscarinic antagonism0 / 4
Embryofetal risk2 / 4

Legacy pregnancy categoryC

Defining liabilityHyperglycemia, infection, osteoporosis and potentially severe mood, sleep or psychotic effects.

Mechanism of action: Dexamethasone ballicule

Dexamethasone ballicule: receptor binding, kinetics and half-life diagram

Open Dexamethasone in the interactive console ↗

Memory aids: mascots and interaction avatars

Dexamethasone DECADRON mascot mnemonic cartoon
“Dex, a metal Decahedron”
cushingoid moon face → corticosteroid
Dexamethasone CYP3A4 inducer avatar
CYP3A4 inducer (moderate)

Open Dexamethasone in the interactive console ↗